MorphoSys (ETR:MOR) has been given a €120.00 ($139.53) price target by JPMorgan Chase & Co. in a report issued on Wednesday, Borsen Zeitung reports. The brokerage presently has a “buy” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 30.29% from the company’s current price.
MOR has been the subject of several other reports. Independent Research set a €96.00 ($111.63) target price on MorphoSys and gave the company a “neutral” rating in a report on Thursday, March 14th. Berenberg Bank set a €108.00 ($125.58) target price on MorphoSys and gave the company a “neutral” rating in a report on Thursday, February 28th. Deutsche Bank set a €125.00 ($145.35) target price on MorphoSys and gave the company a “buy” rating in a report on Tuesday, January 29th. Goldman Sachs Group set a €114.00 ($132.56) target price on MorphoSys and gave the company a “neutral” rating in a report on Friday, January 18th. Finally, Royal Bank of Canada set a €65.00 ($75.58) target price on MorphoSys and gave the company a “sell” rating in a report on Thursday, March 14th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. MorphoSys presently has an average rating of “Hold” and an average price target of €100.78 ($117.18).
ETR MOR opened at €92.10 ($107.09) on Wednesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.47 and a quick ratio of 8.27. The firm has a market capitalization of $2.86 billion and a P/E ratio of -51.40. MorphoSys has a one year low of €76.45 ($88.90) and a one year high of €124.90 ($145.23).
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Read More: Understanding Stock Ratings
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.